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INTRODUCTION
American Cancer Society has estimated the incidence of
adult Central Nervous System (CNS) tumors in the year
2013 as 23,130 and deaths of 14,080 in United States of
America.1 Primary CNS tumors are comprised of
gliomas predominantly. Brain tumors account for 85% to
90% of all primary central nervous system tumors.2
Oligodendrogliomas are tumors of supporting oligoden-
drocytes. Though they are uncommon, yet comprise the
third most common primary brain glial tumor after
glioblastoma multiforme and astrocytomas. Oligoden-
drogliomas constitute between 5 - 10% of all brain
gliomas.3,4
There is a convincing evidence that the incidence of
oligodendrogliomas are increasing due to better
diagnostic accuracy. It is believed that various gliomas
reported in the past were in fact oligodendrogliomas.5-8
It has been shown that various mixed gliomas with
oligodendroglial components like anaplastic oligoastro-
cytomas, behave similarly as pure oligodendrogliomas.9
Oligodendroglial tumors are frequently encountered in
the fourth to sixth decades, with an average age at
diagnosis of approximately 45 years. Median overall
survival for Grade-II and Grade-III tumors is 10 years
and 3 - 5 years, respectively.5,10,11
World Health Organization (WHO) has classified
oligodendrogliomas into low grade well-differentiated
oligodendrogliomas and oligoastrocytomas (WHO
grade-II), and Anaplastic Oligodendrogliomas (AOs) and
Anaplastic Oligoastrocytomas (AOAs) (WHO grade-III).
High-grade tumors demonstrate increased cellularity,
show high mitotic activity, nuclear atypia, vascular
proliferation, and frequent tumor necrosis.5
Molecular Markers: Allelic co-deletion of 1p/19q in
oligodendrogliomas is a very common phenomenon.
About 50 - 60% of the tumors demonstrate this
molecular signature on paraffin-embedded tissues. Co-
deleted tumors are shown to be more sensitive to
alkylator-based chemotherapies.12-14 Other molecular
markers like mutation of Isocitrate Dehydrogenase
(IDH-1 and 2), as well as O,6-Methylguanine-DNA
Methyltransferase (MGMT) promoter methylation are
considered as good prognostic markers in Oligoden-
drogliomas.15-18
Computed Tomography (CT Scan): Typically on CT
scan, 60 - 70% of oligodendrogliomas appear hypodense
or isodense, with poor contrast enhancement. Some
degree of contrast enhancement has been reported to
occur in 24 - 66% of cases. Peri-tumor edema is usually
mild or absent. A rare intraventricular oligodendro-
gliomas however, have a typical hyperdense appear-
ance. There are frequent demonstrable cystic changes
and hemorrhage in the tumor on CT scan. Oligoden-
droglioma is very typical for developing intra-tumoral
calcifications, which may appear as coarse, punctate or
linear on CT scan.8,19,20
Magnetic Resonance Imaging (MRI): MRI is the
investigation of choice in neuroimaging. Oligodendro-
glioma is typically hypointense on T1-weighted images
and hyperintense on T2-weighted images, often well
demarcated with little peri-tumoral edema (Figure 1).
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ABSTRACT
Anaplastic Oligodendroglioma / Anaplastic Oligoastrocytoma (AO/AOA) is a WHO Grade-III primary brain tumor. These
tumors comprise about 5 - 10% of all gliomas, which make them the third most common primary brain tumors after
glioblastoma multiforme and astrocytomas. For many years standard of treatment remained Maximum Safe Resection
(MSR) followed by Radiotherapy (RT). These tumors have also been known to be sensitive to alkylator-based
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are responsive to chemotherapy in recurrent or progressive setting. Recently, up front chemotherapy has been added to
standard post-surgery RT. It has been found that subset of AO/AOA having 1p/19q co-deletion responded very well to the
addition of chemotherapy. This substantial benefit in terms of median Overall Survival (OS) and median Progression Free
Survival (PFS) have intrigued the personalized treatment of AO/AOA on the basis of molecular signature markers.
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MRI is more sensitive than CT scan for demonstrating
brain matter abnormalities and enhancement. These
tumors are heterogeneous in appearance on imaging
due to the presence of varying degrees of intra-tumoral
hemorrhage, areas of cystic degeneration, and/or
calcifications.8,21,22
No correlation has been found between pattern of
contrast enhancement and 1p/19q co-deletion status.
However, tumors with 1p/19q co-deletion are associated
with infiltrative borders on T1-weighted MRI images and
presence of intra-tumor calcification, whereas tumors
having 1p/19q non co-deletion typically have a distinct
border and a uniform signal on T1/T2-weighted
images.6,8,23 It is important, however, to emphasize that
none of these imaging findings are specific and only
tissue diagnosis will settle the issue.
It is worth mentioning that post-surgical MRI should be
done within 72 hours for documentation of extent of the
resection. Otherwise, four weeks post-surgery imaging
will be the imaging timeline.
Positron Emission Tomography (PET) Scan: In
general, brain PET scan is a functional imaging modality
that can provide quantitative information regarding
glucose metabolism, blood flow, and amino acid
metabolism.
Positron-emitting radio-isotope Carbon-11-Methionine
(11C-MET) PET has been reported to be useful in
discriminating oligodendroglioma patients being
followed for residual / recurrent tumor as opposed to
radiotherapy-related necrosis. Functional imaging is
also invaluable in determining the degree of malignancy
(standard uptake values), guiding surgeons to obtain
biopsy from most malignant area, and monitoring
conversion to higher grades.24-27
In future, PET/MRI fusion will be an invaluable tool for
more accurate treatment planning in state of the art
radiotherapy.
Literature Search Strategy: Literature was reviewed
regarding the standard therapy manually using the
library and online through Index Medicus, MEDLINE/
PubMed and EMBASE database for the literature
published till August 31, 2013. Literature search included
randomized control trial, meta-analysis, systemic review,
retrospective case series, practice guidelines and review
articles. MeSH keywords used for the search included
brain tumors, oligodendroglioma, oligoastrocytoma,
management of brain neoplasm, chemotherapy and
radiation therapy.
The standard of care for AO/AOA is Maximal Safe
Resection (MSR) followed by adjuvant radiotherapy (RT)
and chemotherapy.
Surgery: Surgery is the most important component of
overall management of gliomas. Surgical goal for
oligodendroglioma should be gross total removal, if the
tumor can be safely resected.28-32 Evidence has
indicated that a more complete resection of tumor is
associated with better survival.33-36
It is absolutely essential to obtain tissue for accurate
histopathological diagnosis. Tumor resection facilitates
in reducing the mass effect and improving related
symptoms and neurological deficits. Gliomas are
frequently heterogeneous in grade and histology, tumor
resection may also reduce sampling errors that may
occur with biopsy alone.28,30,36
Radiotherapy and Chemotherapy: Radiotherapy has
long been a standard of care for these gliomas after
surgery. Randomized controlled trials have clearly
demonstrated the benefits of adding RT.37-39
It is known for about more than two decades that these
tumors are sensitive to a combination of chemotherapy
drugs consisting of Procarbazine, Lomustine and
Vincristine (PCV) chemotherapy when responses were
documented for small series of patients with recurrent
tumors and later established by prospective studies.40,41
These findings were the backbone for conducting
Randomized Controlled Trials (RCT) in AO/AOAs to
study the role of chemotherapy in the adjuvant setting.
Two latest RCTs have shown that addition of
chemotherapy to the standard treatment of surgery and
radiotherapy has dramatic results in the outcomes of
these tumors. Radiation Therapy Oncology Group
(RTOG) 9402 trial randomized 291 eligible AO/AOAs
patients into two arms after surgery. Experimental arm
comprised of 148 patients who received 04 cycles of
dose-intense PCV chemotherapy followed by RT.
Control arm had 143 patients who received standard
adjuvant RT. Radiation doses in both arms were
standardized as 59.4 Gy in 33 fractions of 1.8 Gy, 5 days
a week, over 6.5 weeks. Both arms were well balanced
in terms of age, gender, performance status, extent of
resection and 1p/19q co-deletion status.42 Results for
the entire cohort revealed that median Overall Survival
(OS) was the same for both arms: 4.6 years for
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Figure 1: Axial MR images of a cystic tumor, found to be an anaplastic
oligodendroglioma. (A) Unenhanced T1-weighted image, showing varying
degrees of hypo intensity. (B) T2 -weighted image showing hyper intensity,
especially of the central cyst.
chemotherapy + RT and 4.7 years for RT, Hazard Ratio
(HR) of 0.79 [95% Confidence Interval (CI) 0.6 - 1.04,
p=0.10]. However, patients with 1p/19q co-deletions
lived twice as long with PCV chemotherapy followed by
radiation as opposed to radiation alone (median OS 14.7
years versus 7.3 years, respectively [HR 0.59 (p = .03)].
Median overall survivals of 2.6 years and 2.7 years were
not significantly different in patients without such
deletions in the experimental and controlled arms [HR
0.85; 95% CI, 0.58 - 1.23 (p = .39)].
European Organization for Research and Treatment of
Cancers (EORTC) 26951 trial randomized 368 patients
of AO and AOA post-surgery, to receive either 59.4 Gy
radiotherapy alone or radiotherapy followed by six
cycles of PCV chemotherapy.43 The results of this trial
are not different from RTOG 9402 study. A total of 80
patients out of 316 were found to have 1p/19q co-
deleted tumors. In these patients with the 1p/19q co-
deletions, median Progression Free Survival (PFS) was
significantly prolonged with the addition of PCV
chemotherapy. Median OS was 112 months with
radiation alone, but had not been reached in RT and
chemotherapy arm for co-deleted tumors at the time of
publication. This translated into a dramatic 44%
reduction in risk of Death Rates (HR = 0.56). Among
those patients having 1p/19q non co-deletions, median
OS was not different significantly.
DISCUSSION
Anaplastic oligodendrogliomas/anaplastic oligo-astro-
ctytomas can be divided into two groups on the basis of
molecular signature of 1p/19q co-deletion which has
consistently shown to be a prognostic and predictive
marker in AO/AOAs.12,42-44 Long-term follow-up from the
two large randomized trials have consistently shown that
patients with newly diagnosed AO/AOAs have
dramatically longer OS if PCV chemotherapy is added to
standard radiation therapy. The benefit was greatest
among patients with tumors that contain the signature
chromosome 1p and 19q deletions, which occurs in
about 50 - 60% of patients with this type of glioma.12-14
Patients with the co-deletions experienced a 44%
reduction in the risk of death, compared with a 25% risk
reduction among all 368 patients in the European
Organization for Research and Treatment of Cancer
(EORTC) 26951 trial.42 These results have opened the
venue for personalized medicine, not based on histology
but the molecular signatures. Other studies have also
proven the prognostic significance of molecular markers
like 1p/19q and IDH 1/2 status.9
These two recently reported trials have used PCV
chemotherapy which is an old and a very toxic regimen.
In fact about 33 - 38% of patients in the two trials were
not able to complete their chemotherapies due to PCV-
induced grade III and IV hematologic toxicities.42,43 The
most important question now is to use more toxic PCV
regimen or temozolomide which is significantly less
toxic, oral alkylating agent chemotherapy in anaplastic
oligodendroglioma with 1p/19q co-deletion.
Grade-IV gliomas (Glioblastoma Multiforme) have
shown significant survival advantage with the use of
concurrent and adjuvant Temozolomide with radiation.45
However, there is no head to head trial in oligodendro-
gliomas to determine whether molecular signature in
AO/AOAs, predicting response to chemotherapy is a
class effect or is unique to PCV chemotherapy.
The German NOA-4 trial has shown that PCV was not
superior to Temozolomide for Grade-III gliomas.46 The
critique, however, is that there is limited follow-up with
only 43% of patients have reached the primary end point
of Time to Treatment Failure (TTF). Also, it was an
underpowered trial to reliably show any difference
between the two regimens.
Studies have shown that 1p/19q co-deleted AO/AOAs
who receive adjuvant RT and on progression receive
PCV chemotherapy, have response duration ranging
from 12 to 24 months.47-49 Hence, both RTOG 9402 and
EORTC 26951 studies have shown major improvement
in outcome for 1p/19q co-deleted tumors when RT +
PCV chemotherapy was employed in the adjuvant
setting up front as opposed to adding PCV on
progression.
Therefore, it is evidence-based to conclude that 1p/19q
co-deleted AO/AOAs should now be treated with
adjuvant RT + chemotherapy. PCV and temozolomide
are not being compared head to head in a large
randomized trial, assuming that combined chemo-
irradiation with temozolomide provides equivalent
results compared with RT+PCV which remains, however,
a leap of faith.
Another important question is whether 1p/19q non co-
deleted tumors should be treated differently? In both
trials (RTOG 9402 and EORTC 26951), no survival
benefit was identified with the addition of PCV
chemotherapy to RT. However, a meaningful analysis
will require a large sample size. In an ongoing current
trial CATNON (Concurrent and Adjuvant Temozolomide
chemotherapy in 1p/19q non co-deleted anaplastic
glioma) will be able to answer this question. Till the
results of such trial are published, addition of
chemotherapy to standard postoperative RT in




cytomas (AO/AOAs) should be stratified on the basis of
molecular signature 1p/19q co-deletion status. Post-
surgical decision of adding chemotherapy to standard
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RT should be the standard of care in co-deleted tumors.
Until the results of randomized-controlled trials like
CANTON, non-co-deleted tumors should be discussed
in multi-disciplinary tumor boards for the individualized
decision of adding chemotherapy to RT.
A simplified treatment algorithm for newly diagnosed
AO/AOAs postsurgery is given below:
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